

---

## DEFINITIONS

---

*In this prospectus, unless the context otherwise requires, the following terms and expressions have the meanings set forth below.*

“404 Company”	CNNC 404 Company Limited (中核四〇四有限公司), a company incorporated under the laws of the PRC on May 24, 1986, a shareholder of our Company and a wholly-owned subsidiary of CNNC
“Anhui Young-Hearty”	Anhui Young-Hearty Medical Appliance & Equipment Co. Ltd (安徽養和醫療器械設備有限公司), a company incorporated under the laws of PRC on July 2, 2002, and a wholly-owned subsidiary of Headway
“Application Form(s)”	<b>WHITE</b> application form(s), <b>YELLOW</b> application form(s) and <b>GREEN</b> applications form(s), or where the context so requires, any of them, relating to the Hong Kong Public Offering
“Arbitration Law”	the Arbitration Law of the PRC, as amended, supplemented or otherwise modified from time to time
“Articles of Association” or “Articles”	the articles of association of our Company (as amended) which was passed at the 2016 annual general meeting on March 31, 2017 and shall become effective on the Listing Date, a summary of which is set out in Appendix V to this prospectus
“Baoyuan Investment”	China Baoyuan Investment Co., Ltd. (中國寶原投資有限公司, previously known as “中國中核寶原資產控股公司”), a company incorporated under the laws of the PRC on January 20, 1988 and a shareholder of our Company and a wholly-owned subsidiary of CNNC
“BINE”	BINE High-Tec Co., Ltd. (北京核二院比尼新技術有限公司), formerly known as Beijing Nuclear Engineering Research and Design Institute BINE New Technology Company (北京核工程研究設計院比尼新技術公司), a company incorporated under the laws of the PRC on August 7, 1990 and owned by our Company as to 80% of its equity interest as of the Latest Practicable Date
“BNIBT”	Beijing North Institute of Biological Technology Co., Ltd. (北京北方生物技術研究所有限公司), formerly known as Northern Immunologic Reagent Research Institute (北方免疫試劑研究所), a company incorporated under the laws of the PRC on June 6, 1985 and a wholly-owned subsidiary of our Company
“Board” or “Board of Directors”	the board of Directors of our Company

---

## DEFINITIONS

---

“business day”	a day on which banks in Hong Kong are generally open for normal banking business to the public (excluding Saturday, Sunday or public holidays in Hong Kong)
“CAGR”	compound annual growth rate
“CAIC”	China Aerospace Investment Co., Ltd. (航天科工資產管理有限公司), a company incorporated under the laws of the PRC on October 29, 2009 and a shareholder of our Company
“CAIIF”	Beijing Aerospace Industry Investment Fund LLP (北京航天產業投資基金 (有限合夥)), a limited liability partnership incorporated under the laws of the PRC on March 3, 2010 and a shareholder of our Company
“CAS”	China’s Accounting Standards for Business Enterprises
“CBRC”	the China Banking Regulatory Commission
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct clearing participant or general clearing participant
“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant
“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant who may be an individual, joint individuals or a corporation
“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“CCCC”	CNNC Isotope & Radiation (Changchun) Radiation Technology Co., Ltd. (中核同輻 (長春) 輻射技術有限公司), a company incorporated under the laws of PRC on January 25, 2013 and a wholly-owned subsidiary of our Company
“CFDA”	the China Food and Drug Administration of the PRC (中華人民共和國國家食品藥品監督管理總局), formerly known as the State Food and Drug Administration of the PRC (國家食品藥品監督管理局) and currently transformed to the State Administration of Market Regulation (國家市場監督管理總局) according to the Notice of the State Council regarding the Establishment of Organizations (國務院關於機構設置的通知) (Guo Fa [2018] No.6) issued by the State Council on March 24, 2018

---

## DEFINITIONS

---

“China” or “PRC”	the People’s Republic of China, for the purpose of this prospectus, excluding Hong Kong, Macau and Taiwan
“China Isotope”	China Isotope Company (中國同位素公司), a company owned by the whole people incorporated under the laws of the PRC on January 31, 1983, the predecessor of our Company
“China Isotope Company Limited”	China Isotope Company Limited (中國同位素有限公司), a limited liability company restructured from China Isotope on December 4, 2007, the predecessor of our Company
“China North Nuclear Fuel”	China North Nuclear Fuel Co., Ltd. (中核北方核燃料元件有限公司), a company incorporated under the laws of PRC on May 30, 1985 and a wholly-owned subsidiary of CNNC
“CIAE”	China Institute of Atomic Energy (中國原子能科學研究院), a public institute established under the laws of the PRC in 1950, which is directly controlled and managed by CNNC and a promoter and substantial shareholder of our Company
“CIC Lab”	Beijing CIC Clinical Laboratory Co., Ltd. (北京中同藍博臨床檢驗所有限公司), formerly known as Beijing CIC Clinical Lab (北京中同藍博臨床檢驗所), a company incorporated under the laws of PRC on March 2, 2007, and a wholly-owned subsidiary of our Company
“CIRP”	China Institute for Radiation Protection (中國輻射防護研究院), a public institute established under the laws of the PRC on July 13, 1962, which is directly controlled and managed by CNNC
“CNEIC”	China Nuclear Energy Industry Corporation (中國原子能工業有限公司), a company incorporated under the laws of the PRC on January 15, 1982 and a wholly-owned subsidiary of CNNC
“CNGT”	Chengdu Gaotong Isotope Co., Ltd. (CNNC) (成都中核高通同位素股份有限公司), a company incorporated under the laws of the PRC on June 11, 2002 and owned by our Company as to 90.38% of its equity interest as of the Latest Practicable Date
“CNNC”	China National Nuclear Corporation (中國核工業集團有限公司, previously known as “中國核工業集團公司”), a company incorporated under the laws of the PRC on June 29, 1999, a promoter and the controlling shareholder of our Company
“CNNCFC”	CNNC Finance Company Limited (中核財務有限責任公司), a company incorporated under the laws of the PRC on July 21, 1997 and controlled by CNNC

---

## DEFINITIONS

---

“CNNC Financial Leasing Company”	CNNC Financial Leasing Co., Ltd. (中核融資租賃有限公司), a company incorporated under the laws of the PRC on December 22, 2015 and controlled by CNNC
“CNNC Fund”	Beijing CNNC Industry Investment Fund (LLP) (北京中核產業投資基金(有限合夥)), a limited liability partnership incorporated under the laws of the PRC on December 10, 2015 and a shareholder of our Company and a non-wholly-owned subsidiary of CNNC
“CNNC Jianzhong Nuclear Fuel”	CNNC Jianzhong Nuclear Fuel Co., Ltd. (中核建中核燃料元件有限公司), a company incorporated under the laws of PRC on June 6, 1986 and a wholly-owned subsidiary of CNNC
“CNNC Taizhou”	CNNC (Taizhou) Irradiation Technology Co. Ltd. (中核(泰州)輻照科技有限公司), a company incorporated under the laws of PRC on December 7, 2017, and owned by our Company as to 86% of its equity interest as of the Latest Practicable Date
“CNNC Tongxing”	CNNC Tongxing (Beijing) Nuclear Technology Co., Ltd. (中核同興(北京)核技術有限公司), a company incorporated under the laws of the PRC on March 12, 2010 and owned by our Company and a subsidiary of CNNC as to 51% and 49% of its equity interest, respectively, as of the Latest Practicable Date
“Companies (Winding up and Miscellaneous Provisions) Ordinance”	the Companies (Winding up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company”, “we”, or “us”	China Isotope & Radiation Corporation (中國同輻股份有限公司), a joint-stock limited company restructured from China Isotope Company Limited under the laws of the PRC on December 6, 2011, including its predecessor(s) (if the context requires)
“Company Law” or “PRC Company Law”	Company Law of the People’s Republic of China (中華人民共和國公司法), as amended and adopted by the Standing Committee of the Tenth National People’s Congress on October 27, 2005 and effective on January 1, 2006, as amended, supplemented or otherwise modified from time to time, which was further amended on December 28, 2013 to take effective on March 1, 2014
“Constitution”	the Constitution of the People’s Republic of China, as amended, supplemented or otherwise modified from time to time

---

## DEFINITIONS

---

“CSDCC”	China Securities Depository and Clearing Corporation Limited (中國證券登記結算有限責任公司)
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Designated Persons”	individuals and entities either listed on an official Sanctions list maintained by a Sanctions Authority or owned or controlled by such persons. For avoidance of doubt, Sectoral Sanctions Targets (defined below) are not considered Designated Persons.
“Director(s)”	director(s) of our Company
“Domestic Share(s)”	ordinary share(s) issued by our Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in Renminbi
“EIT Law”	Enterprise Income Tax Law of the People’s Republic of China (中華人民共和國企業所得稅法) (as amended, supplemented or otherwise modified from time to time)
“EPC”	engineering, procurement and construction
“FDA”	Food and Drug Administration of the United States
“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., an independent global market research and consulting company which was founded in 1961 and based in the United States
“Frost & Sullivan Report”	a report prepared by Frost & Sullivan on the Chinese isotopes and irradiation technology application market, which was commissioned by the Company
“Global Offering”	the Hong Kong Public Offering and the International Offering
“GREEN Application Form(s)”	the application form(s) to be completed by the <b>White Form eIPO</b> Service Provider, Computershare Hong Kong Investor Services Limited
“Group,” “our Group,” “we” or “us”	our Company and its subsidiaries (or our Company and any one or more of its subsidiaries, as the context may require) and except where the context indicates otherwise, includes their respective predecessor (if any)
“H Share Registrar”	Computershare Hong Kong Investor Services Limited

---

## DEFINITIONS

---

“H Share(s)”	overseas listed foreign shares in the share capital of our Company with a nominal value of RMB1.00 each, which are to be subscribed for and traded in HK dollars and listed on the Hong Kong Stock Exchange
“Hainan Haiyuan”	CNNC Hainan Haiyuan Development Co., Ltd. (中核海南海原開發有限公司), a company incorporated under the laws of the PRC on January 6, 1989 and owned by our Company and Baoyuan Investment as to 92.65% and 7.35% of its equity interest, respectively, as of the Latest Practicable Date
“Headway”	Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. (深圳市中核海得威生物科技有限公司), a company incorporated under the laws of PRC on August 9, 1996 and owned by our Company (directly and indirectly) and an associate of CNNC as to 54.1% and 27.9% of its equity interest, respectively, as of the Latest Practicable Date
“HK\$” or “HK dollars”	Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong
“HKSCC”	Hong Kong Securities Clearing Company Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited
“HKSCC Nominees”	HKSCC Nominees Limited, a wholly owned subsidiary of HKSCC
“Hong Kong” or “HK”	Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules” or “Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
“Hong Kong Offer Shares”	the 7,997,200 H Shares initially offered by our Company for subscription at the Offer Price pursuant to the Hong Kong Public Offering (subject to reallocation as described in “Structure of the Global Offering”)
“Hong Kong Public Offering”	the offer of the Hong Kong Offer Shares for subscription by the public in Hong Kong (subject to adjustment as described in “Structure of the Global Offering”) at the Offer Price plus brokerage, SFC transaction levy and Hong Kong Stock Exchange trading fee, on and subject to the terms and conditions described in this prospectus and on the Application Forms as further described in “Structure of the Global Offering — Hong Kong Public Offering”
“Hong Kong Stock Exchange” or “Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited

---

## DEFINITIONS

---

“Hong Kong Underwriters”	the underwriters of the Hong Kong Public Offering listed in “Underwriting — Hong Kong Underwriters”
“Hong Kong Underwriting Agreement”	the underwriting agreement on or around Thursday, June 21, 2018, relating to the Hong Kong Public Offering and entered into by, among others, our Company, the Sole Sponsor, the Joint Global Coordinators, the Joint Bookrunners and the Hong Kong Underwriters, as further described in “Underwriting — Underwriting Arrangements and Expenses”
“HTA”	HTA Co., Ltd. (原子高科股份有限公司), formerly known as Beijing HTA Nuclear Techno (北京原子高科核技術應用股份有限公司), a company incorporated under the laws of the PRC on May 18, 2001 and owned by our Company and a subsidiary of CNNC as to 68.28% and 3.02% of its shares respectively as of the Latest Practicable Date, the shares of which are listed on the National Equities Exchange and Quotations (stock code: 430005)
“HTA (Guangzhou)”	HTA (Guangzhou) Isotope Pharmaceutical Co., Ltd. (廣州市原子高科同位素醫藥有限公司), a company incorporated in China under the laws of the PRC on January 24, 2000 and owned by HTA as to 80% of its equity interest as of the Latest Practicable Date
“Huakang Radiation”	Zhangjiagang CNNC Huakang Radiation Co., Ltd. (張家港市中核華康輻照有限公司), formerly known as Zhangjiagang New Radioactive Technology Application Co., Ltd. (張家港市新高輻射技術應用有限公司), a company incorporated under the laws of PRC on November 5, 2002 and owned by our Company (directly and indirectly) as to 52.15% of its equity interest as of the Latest Practicable Date
“IFRS”	International Financial Reporting Standards
“Independent Third Party(ies)”	person(s) or company(ies) which, to the best of our Directors’ knowledge having made all reasonable enquiries, is/are not connected (within the meaning of the Listing Rules) with the Group
“International Offer Shares”	the 71,971,500 Shares initially offered by our Company for subscription or purchase pursuant to the International Offering together with (where relevant) any additional Shares which may be issued by our Company pursuant to the exercise of the Over-allotment Option (subject to reallocation as described in “Structure of the Global Offering”)
“International Offering”	the offer of the International Offer Shares by the International Underwriters outside the United States in offshore transactions in accordance with Regulation S or another available exemption from registration under the US Securities Act, as further described in “Structure of the Global Offering” in this prospectus

---

## DEFINITIONS

---

“International Underwriters”	the group of international underwriters expected to enter into the International Underwriting Agreement to underwrite the International Offering
“International Underwriting Agreement”	the underwriting agreement expected to be entered into on or around June 28, 2018 by, among others, the Company and the International Underwriters, as further described in “Underwriting — The International Offering” in this prospectus
“Isotope (Shanghai)”	China Isotope (Shanghai) Co., Ltd. (中國同位素上海有限公司), a company incorporated under the laws of the PRC on September 16, 1989 and a wholly-owned subsidiary of our Company
“Isotope (Shenzhen)”	China Isotope (Shenzhen) Co., Ltd. (中國同位素深圳有限公司), a company incorporated under the laws of the PRC on March 28, 1985 and a wholly-owned subsidiary of our Company
“Joint Bookrunners”	China International Capital Corporation Hong Kong Securities Limited, CLSA Limited and ABCI Capital Limited
“Joint Global Coordinators”	China International Capital Corporation Hong Kong Securities Limited and CLSA Limited
“Joint Lead Managers”	China International Capital Corporation Hong Kong Securities Limited, CLSA Limited, ABCI Securities Company Limited and China Securities (International) Corporate Finance Company Limited
“Latest Practicable Date”	June 12, 2018, being the latest practicable date prior to the printing of this prospectus for the purpose of ascertaining certain information contained in this prospectus
“Listing”	the listing of our H Shares on the Main Board of the Stock Exchange
“Listing Committee”	the Listing Committee of the Stock Exchange
“Listing Date”	the date, expected to be on or around Friday, July 6, 2018, on which our H Shares are listed and from which dealings in our H Shares are permitted to commence on the Stock Exchange
“Macau”	Macau Special Administrative Region of the PRC
“Main Board”	the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Hong Kong Stock Exchange

---

## DEFINITIONS

---

“Mandatory Provisions”	Mandatory Provisions for Articles of Association of Companies to be Listed Overseas (as amended, supplemented or otherwise modified from time to time) for inclusion in the articles of association of companies incorporated in the PRC to be listed overseas (including Hong Kong), which were promulgated by the former Securities Commission of the State Council (國務院證券委員會) and the former State Commission for Restructuring the Economic Systems (國家經濟體制改革委員會) on August 27, 1994
“MEP”	the Ministry of Environmental Protection of the PRC (中華人民共和國環境保護部) and transformed to the Ministry of Ecology and Environment of the PRC (中華人民共和國生態環境部) according to the Notice of the State Council regarding the Establishment of Organizations (國務院關於機構設置的通知) (Guo Fa [2018] No.6) issued by the State Council on March 24, 2018
“Ministry of Finance” or “MOF”	Ministry of Finance of the PRC (中華人民共和國財政部)
“Ministry of Nuclear Industry”	Ministry of Nuclear Industry of the PRC (中華人民共和國核工業部), which is converted to China Nuclear Industry Corporation and then CNNC, the predecessor of CNNC
“MOFCOM”	Ministry of Commerce of the PRC (中華人民共和國商務部)
“MOHRSS”	the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部)
“National Energy Administration”	the National Energy Administration of the PRC (國家能源局)
“National Medical Insurance Pharmaceuticals Catalog”	The Medicine Catalog for the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2017) (《國家基本醫療保險、工傷保險和生育保險藥品目錄國家(2017)》)
“NDRC”	National Development and Reform Commission of the PRC (中華人民共和國發展和改革委員會)
“NEEQ”	National Equities Exchange and Quotations
“New York Convention”	the Convention on the Recognition and Enforcement of Foreign Arbitral Awards
“NHFPC”	“National Health and Family Planning Commission of the PRC” (中華人民共和國國家衛生和計劃生育委員會)
“NPC”	the National People’s Congress of the PRC (中華人民共和國全國人民代表大會)

---

## DEFINITIONS

---

“NPIC”	Nuclear Power Institute of China (中國核動力研究設計院), a public institute established under the laws of the PRC in 1965, which is controlled and managed by CNNC and a promoter and a substantial shareholder of our Company
“Offer Price”	the final price per Offer Share in Hong Kong dollars (denominated in HKD, exclusive of 1% brokerage fee, 0.0027% SFC transaction levy and 0.005% Hong Kong Stock Exchange trading fee) of not more than HK\$24.20 and expected to be not less than HK\$17.80, at which Hong Kong Offer Shares are to be subscribed, to be determined in the manner further described in “Structure of the Global Offering — Pricing and Allocation”
“Offer Share(s)”	the Hong Kong Offer Shares and the International Offer Shares, together with, where relevant, any additional H Shares which may be issued by our Company pursuant to the exercise of the Over-allotment Option
“Over-allotment Option”	the option expected to be granted by our Company to the International Underwriters, exercisable by the Sole Representative (on behalf of the International Underwriters) pursuant to the International Underwriting Agreement, pursuant to which our Company may be required to sell up to an aggregate of 11,995,300 Shares at the Offer Price to cover, among others, over-allocations in the International Offering, if any, further details of which are described in “Structure of the Global Offering” in this prospectus
“PBOC”	the People’s Bank of China (中國人民銀行), the central bank of the PRC
“PRC GAAP”	generally accepted accounting principles in the PRC
“PRC Legal Advisors”	King & Wood Mallesons
“Pre-IPO Investors”	CNNC Fund, CAIIF and CAIC
“Price Determination Agreement”	the agreement to be entered into by the Joint Global Coordinators (on behalf of the Underwriters) and our Company on the Price Determination Date to record and fix the Offer Price
“Price Determination Date”	the date, expected to be on or around Thursday, June 28, 2018 (Hong Kong time) on which the Offer Price is determined, or such later time as the Joint Global Coordinators (on behalf of the Underwriters) and our Company may agree, but in any event no later than Wednesday, July 4, 2018
“prospectus”	this prospectus being issued in connection with the Hong Kong Public Offering

---

## DEFINITIONS

---

“province”	a province or, where the context requires, a provincial level autonomous region or municipality, under the direct supervision of the central government of the PRC
“Qinshan No. 3 Nuclear Power”	Qinshan No. 3 Nuclear Power Co., Ltd. (秦山第三核電有限公司), a company incorporated under the laws of the PRC on January 31, 1997 and a non-wholly-owned subsidiary of CNNC
“Regulation S”	Regulation S under the US Securities Act
“Relevant Persons”	The Hong Kong Stock Exchange, the Listing Committee and its members, HKSCC, HKSCC Nominees, our shareholders, investors, the Sole Sponsor and the underwriters of the Global Offering.
“Restricted Countries”	Sanctioned Countries and Targeted Countries
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“SAFE”	State Administration of Foreign Exchange of the PRC (中國國家外匯管理局)
“Sanctioned Countries”	countries and territories that are subject to comprehensive US country-based sanctions programs, including Crimea, Cuba, Iran, North Korea, Sudan, and Syria
“Sanctions”	restrictive economic measures imposed by Sanctions Authorities of the US, EU, Hong Kong, and/or Australia against countries, governments, entities, groups and individuals, including measures implemented by such Sanctions Authorities to give effect to UN sanctions
“Sanctions Authorities”	state or supranational authorities that are empowered to enact or are charged with implementing, administering or enforcing Sanctions
“Sanctions Targets”	certain countries, governments, entities, groups and individuals that are subject to Sanctions
“SASAC”	State-owned Assets Supervision and Administration Commission of the State Council (國務院國有資產監督管理委員會)
“SAT”	State Administration of Taxation of the PRC (國家稅務總局)
“Sectoral Sanctions”	EU and US Sanctions measures targeting the financial, defense, and energy sectors of the Russian economy
“Sectoral Sanctions Targets”	entities that are subject to Sectoral Sanctions
“SFC”	the Securities and Futures Commission of Hong Kong

---

## DEFINITIONS

---

“SFO” or “Securities and Futures Ordinance”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, (as amended, supplemented or otherwise modified from time to time)
“Shanghai GMS Pharmaceutical”	Shanghai GMS Pharmaceutical Co., Ltd. (上海欣科醫藥有限公司), a company incorporated under the laws of the PRC on October 7, 1993 and owned by our Company as to 49% of its equity interest as of the Latest Practicable Date
“Shanghai Yuanzi Kexing”	Shanghai Yuanzi Kexing (上海原子科興藥業有限公司), a company incorporated under the laws of the PRC on March 23, 1995 and owned by HTA as to 70% of its equity interest as of the Latest Practicable Date
“Shareholders(s)”	holder(s) of the Share(s)
“Share(s)”	the ordinary shares in the capital of our Company with a nominal value of RMB1.00 each
“Shenzhen CICAM”	Shenzhen CICAM Manufacturing Co., Ltd. (深圳西卡姆同位素有限公司), a company incorporated under the laws of the PRC on August 28, 1992 and owned by Isotope (Shenzhen) as to 49% of its equity interest
“Sichuan Irradiation”	CNNC Isotope & Radiation (Sichuan) Radiation Technology Co., Ltd. (中核同輻(四川)輻射技術有限公司), a company incorporated under the laws of PRC on March 12, 2013 and a wholly-owned subsidiary of our Company
“SME(s)”	small and medium-sized enterprise(s)
“SOE(s)”	state-owned enterprise(s)
“Sole Representative”	China International Capital Corporation Hong Kong Securities Limited
“Sole Sponsor”	China International Capital Corporation Hong Kong Securities Limited
“Special Regulations”	the Special Regulations of the State Council on the Overseas Offering and Listing of Shares by Joint Stock Limited Companies (國務院關於股份有限公司境外募集股份及上市的特別規定), promulgated by the State Council on August 4, 1994
“Stabilizing Manager”	China International Capital Corporation Hong Kong Securities Limited
“State Council”	the State Council of the People’s Republic of China (中華人民共和國國務院)
“Supervisor(s)”	member(s) of our Supervisory Committee
“Supervisory Committee”	the supervisory committee of our Company

---

## DEFINITIONS

---

“Suzhou Radiation”	Suzhou CNNC Huadong Radiation Co., Ltd. (蘇州中核華東輻照有限公司), formerly known as Wujiang Radiation Center of Suzhou Medical College (蘇州醫學院吳江輻照中心), a company incorporated under the laws of the PRC on December 15, 1994 and owned by our Company as to 51.59% of its equity interest as of the Latest Practicable Date
“Targeted Countries”	countries or territories that are subject to targeted country-based Sanctions, but that are not one of the Sanctioned Countries.
“Track Record Period”	the three years ended December 31, 2015, 2016 and 2017
“US” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US Securities Act”	the United States Securities Act of 1933 (as amended) and the rules and regulations promulgated thereunder
“Underwriters”	the Hong Kong Underwriters and the International Underwriters
“Underwriting Agreements”	the Hong Kong Underwriting Agreement and the International Underwriting Agreement
“UNSC”	the UN Security Council
“US\$” or “US dollars”	United States dollars, the lawful currency of the United States
“ <b>WHITE</b> Application Form(s)”	the application form(s) for use by the public who require(s) such Hong Kong Offer Shares to be issued in the applicant’s own name
“ <b>White Form eIPO</b> ”	the application for Hong Kong Offer Shares to be issued in the applicant’s own name by submitting applications online through the designated website of <b>White Form eIPO</b> at <a href="http://www.eipo.com.hk">www.eipo.com.hk</a>
“ <b>White Form eIPO</b> Service Provider”	Computershare Hong Kong Investor Services Limited
“ <b>YELLOW</b> Application Form(s)”	the application form(s) for use by the public who require(s) such Hong Kong Offer Shares to be deposited directly into CCASS
“Yunke Pharm”	Chengdu Yunke Pharmaceutical Co., Ltd. (成都雲克藥業有限責任公司), a company incorporated under the laws of PRC on July 5, 2001 and owned by NPIC as to 47.89% of its equity interest as of the Latest Practicable Date

In this prospectus, the terms “associate(s),” “close associate(s),” “connected person(s),” “core connected person(s),” “connected transaction(s),” “controlling shareholder(s)” and “substantial shareholder(s)” shall have the meanings given to such terms in the Hong Kong Listing Rules, unless the context otherwise requires.

---

## **DEFINITIONS**

---

Certain amounts and percentage figures included in this prospectus have been subject to rounding. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them. Any discrepancies in any table or chart between the total shown and the sum of the amounts listed are due to rounding.

For ease of reference, the names of the PRC established companies or entities, laws or regulations have been included in this prospectus in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail.